Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Noonan Syndrome 6 × capmatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 12 Lung Neoplasms 4 Melanoma 3 Adenocarcinoma of Lung 3 Noonan Syndrome 6 1 Neoplasms 1 Neoplasm Metastasis 1 Malignant Non-small Cell Neoplasm of Lung Stage IV 1 Kidney Neoplasms 1

Interventions

regorafenib 1 entrectinib 1 ceritinib 1 capmatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02587650 2020-01-27

Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma

University of California, San Francisco

Phase 2 Terminated

1 enrolled 7 charts

Noonan Syndrome 6, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡